HaystackAnalytics in partnership with Sapphire Diagnostics has launched its Genomic Centre of Excellence (GCE) in Goa, empowering the region for the first time with Next Generation Sequencing-based infection diagnostics, stated a press release.
Infectious diseases pose a challenge to clinicians each day with confounding clinical presentations and cascading diagnostics in a disparate healthcare ecosystem. Coupled with antimicrobial resistance, hospital-acquired infections, emerging and re-emerging infections,
and polymicrobial infections, the diagnostic precision required for early institution of tailored therapy for a patient is not achieved by conventional methods.
The Sapphire Diagnostics GCE addresses this directly by bringing infexn®️-NGS, a HaystackAnalytics flagship innovation. A direct-from-sample, comprehensive NGS-based pathogen detection assay, which is deployed fully on-site from day one ensures faster delivery of accurate results for prompt clinical decision making. This marks a shift toward a more self-sufficient healthcare system in Goa.
“Every day we wait for the right diagnosis is a day lost to ineffective or misdirected treatment and that’s exactly what we’re here to fix in the spectrum of infectious diseases. Goa’s doctors have long managed complex infection cases without easy access to advanced genomic diagnostics locally. That changes now.” says Dr. Mahua Dasgupta, Director, Medical Affairs (Infectious Diseases), HaystackAnalytics.
“At Sapphire Diagnostics, we have always believed that patients in Goa deserve world-class diagnostic care.
This partnership with HaystackAnalytics allows us to offer genomic-level infectious disease testing locally, which is a significant step forward for clinical care in this region,” says Dr. Sunayana Shet from Sapphire Diagnostics. infexn®️-NGS has processed 30,000+ samples across India’s leading institutions, with 20+ GCEs now live across the country. This launch strengthens Goa’s diagnostic infrastructure and brings the region closer to the standard of infectious disease care available in India’s major cities.
